Copyright © Inderes 2011 - present. All rights reserved.

Biohit

3.58 EUR

-0.56 %

4,890 following

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.56 %
+17.38 %
+31.62 %
+30.18 %
+56.33 %
+56.33 %
+104.57 %
+79.00 %
-31.15 %

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more
Market cap
54.41M EUR
Turnover
30.07K EUR
P/E (adj.) (25e)
25.81
EV/EBIT (adj.) (25e)
19.04
P/B (25e)
3.78
EV/S (25e)
3.05
Dividend yield-% (25e)
0.97 %
Coverage
Recommendation
Reduce
Target price
3.70 EUR
Updated
2025-11-13
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2025-11-13

Latest extensive report

Released: 2025-01-15

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11/2
2026

Annual report '25

3/6
2026

General meeting '26

5/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
What terrible things do you think HS’s visionaries saw back then? It would be very kind if you could provide a short summary of the matters you are referring to. A link to the source is, of course, always a bonus.
yesterday
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
5
Yes.. Hahtela has, in my opinion, indeed moved the company forward very well, and I believe the pace will accelerate.
19 hours ago
by Tunturisusi
4
Certainly, there are benefits to a dominant voting power, but could Osmo S do something like accumulate enough shares to then make a final takeover bid for the entire company? Since he has money from previous deals and no more is needed to run the business through share issues… and...
12 hours ago
by Ehemot
3
Would redemption require 90% of the shares or voting power, or both? Now that there are two classes of shares and the shares with more voting power are almost all held by Suovaniemi and Hefe, Suovaniemi could quite easily acquire 90% of the voting power, perhaps even with a small...
10 hours ago
by Onni Mäihä
2
It is indeed. But perhaps as a shareholder, I would hope for a different kind of development.
19 hours ago
by Junkbondking
2
I always go back to those HS Vision articles from a couple of years ago, and in their light, Osmo’s purchases are terrifying.
12/2/2025, 2:53 PM
by Junkbondking
2
I myself was initially somewhat wary of the risks of a large majority owner, but upon reflection, I think that it might be precisely the recipe for Biohit to most effectively capture the market. No pressure from institutional investors for dividends, and genuinely going global with...
12/2/2025, 2:43 PM
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.